1. Bank of America maintains a Buy rating on LLY despite slight price target cut. 2. Orfoglipron launch is expected in 2026, offering significant revenue potential. 3. Government agreement may increase patient access, boosting long-term growth. 4. Market may underestimate LLY's next obesity growth chapter. 5. Lilly's strategies focus on mitigating market challenges and expanding coverage.
FAQ
Why Bullish?
Bank of America's positive outlook reflects strong growth potential, similar to Zepbound's launch.
How important is it?
The analysis suggests significant growth opportunities for LLY, influencing investor sentiment.
Why Long Term?
Orfoglipron's expected launch and patient growth will shape long-term success.